🇺🇸 Ventavis in United States

7,614 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 7,614

Most-reported reactions

1. Death — 2,150 reports (28.24%)
2. Dyspnoea — 1,315 reports (17.27%)
3. Headache — 694 reports (9.11%)
4. Cough — 570 reports (7.49%)
5. Pulmonary Arterial Hypertension — 534 reports (7.01%)
6. Fatigue — 533 reports (7%)
7. Dizziness — 514 reports (6.75%)
8. Pneumonia — 454 reports (5.96%)
9. Nausea — 437 reports (5.74%)
10. Pulmonary Hypertension — 413 reports (5.42%)

Source database →

Frequently asked questions

Is Ventavis approved in United States?

Ventavis does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ventavis in United States?

Meshalkin Research Institute of Pathology of Circulation is the originator. The local marketing authorisation holder may differ — check the official source linked above.